| DM population | p value | Non-DM population | p value | ||
---|---|---|---|---|---|---|
Complete revascularization (N = 893) | Incomplete revascularization (N = 1110) | Complete revascularization (n = 1833) | Incomplete revascularization (N = 1680) | |||
Age, years | 65.1 ± 9.4 | 65.2 ± 9.4 | 0.797 | 62.3 ± 10.6 | 65.1 ± 10.4 |  < 0.001 |
Male | 572 (64.1%) | 725 (65.3%) | 0.589 | 1265 (69.0%) | 1179 (70.2%) | 0.476 |
Body mass index, kg/m2 | 25.0 ± 3.1 | 24.9 ± 3.4 | 0.465 | 24.7 ± 3.0 | 24.7 ± 3.0 | 0.687 |
Hypertension | 654 (73.2%) | 848 (76.4%) | 0.116 | 1070 (58.4%) | 1051 (62.6%) | 0.012 |
Dyslipidemia | 538 (60.2%) | 652 (58.7%) | 0.524 | 965 (52.6%) | 924 (55.0%) | 0.173 |
Chronic kidney disease | 310 (34.7%) | 427 (38.5%) | 0.092 | 422 (23.0%) | 530 (31.5%) |  < 0.001 |
Peripheral vessel disease | 15 (1.7%) | 34 (3.0%) | 0.065 | 19 (1.0%) | 28 (1.7%) | 0.140 |
Current smoker | 181 (20.3%) | 278 (25.0%) | 0.140 | 496 (27.1%) | 456 (27.1%) | 0.986 |
Prior myocardial infarction | 12 (1.3%) | 22 (2.0%) | 0.355 | 30 (1.6%) | 49 (2.9%) | 0.015 |
Prior stroke | 93 (10.4%) | 131 (11.8%) | 0.364 | 111 (6.1%) | 155 (9.2%) |  < 0.001 |
Family history of CAD | 41 (4.6%) | 71 (6.4%) | 0.099 | 100 (5.5%) | 112 (6.7%) | 0.151 |
LVEF, % | 60.9 ± 10.5 | 59.5 ± 11.1 | 0.006 | 62.2 ± 8.9 | 60.6 ± 10.2 |  < 0.001 |
HbA1c, % | 7.5 ± 1.6 | 7.5 ± 1.5 | 0.449 | – | – | – |
Presenting with cardiogenic shock | 0 (0.0%) | 7 (0.6%) | 0.046 | 1 (0.1%) | 4 (0.2%) | 0.320 |
Presentations | Â | |||||
 Unstable angina | 431 (48.3%) | 480 (43.2%) | 0.118 | 925 (50.5%) | 850 (50.6%) | 0.069 |
 Stable angina | 398 (44.6%) | 530 (47.7%) | 820 (44.7%) | 719 (42.8%) | ||
 Silent ischemia | 64 (7.1%) | 100 (9.1%) | 88 (4.8%) | 111 (6.6%) | ||
Complexity of disease | Â | |||||
 Left main disease | 60 (6.7%) | 86 (7.7%) | 0.427 | 120 (6.5%) | 133 (7.9%) | 0.133 |
 Multivessel disease | 447 (50.1%) | 836 (75.3%) |  < 0.001 | 703 (38.4%) | 1133 (67.4%) |  < 0.001 |
 At least 1 bifurcation | 367 (41.1%) | 500 (45.0%) | 0.084 | 648 (35.4%) | 774 (46.1%) |  < 0.001 |
 At least 1 long lesion | 297 (33.3%) | 465 (41.9%) |  < 0.001 | 438 (23.9%) | 646 (38.5%) |  < 0.001 |
 At least 1 small vessel | 473 (53.0%) | 644 (58.0%) | 0.027 | 684 (37.3%) | 841 (50.1%) |  < 0.001 |
 Stent number per person | 1.7 ± 1.0 | 1.8 ± 1.0 | 0.014 | 1.5 ± 0.8 | 1.8 ± 1.0 |  < 0.001 |
 Total stent length, mm | 42.0 ± 28.4 | 45.8 ± 28.1 | 0.003 | 35.1 ± 23.4 | 43.3 ± 27.5 |  < 0.001 |
 Baseline SYNTAX score | 10.8 ± 8.0 | 18.5 ± 8.8 |  < 0.001 | 9.5 ± 7.0 | 17.4 ± 10.1 |  < 0.001 |
 Residual SYNTAX score | 0.0 ± 0.0 | 8.5 ± 6.2 |  < 0.001 | 0.0 ± 0.0 | 7.6 ± 6.0 |  < 0.001 |
Medication at discharge | ||||||
 Statin | 763 (85.4%) | 929 (83.7%) | 0.312 | 1615 (88.1%) | 1472 (87.6%) | 0.696 |
 ACE-I/ARB | 574 (64.3%) | 701 (63.2%) | 0.636 | 1016 (55.4%) | 981 (58.4%) | 0.082 |
 Beta-blocker | 467 (52.3%) | 654 (58.9%) | 0.003 | 939 (51.2%) | 986 (58.7%) |  < 0.001 |
 Calcium-channel blocker | 295 (33.0%) | 336 (30.3%) | 0.202 | 554 (30.2%) | 493 (29.3%) | 0.595 |
DM medication at discharge | ||||||
 Insulin | 128 (14.3%) | 181 (16.3%) | 0.249 | – | – | – |
 Sulfonylurea | 245 (27.4%) | 311 (28.0%) | 0.811 | – | – | – |
 Metformin | 298 (33.3%) | 372 (33.5%) | 0.984 | – | – | – |
 DPP4 inhibitor | 116 (13.0%) | 135 (12.2%) | 0.625 | – | – | – |
 Alpha-glucosidase inhibitor | 35 (3.9%) | 57 (5.1%) | 0.236 | – | – | – |
 TZD | 21 (2.3%) | 22 (2.0%) | 0.680 | – | – | – |